MIRACLE
Magnetic Isolation and moleculaR Analysis of single CircuLating and disseminated tumor cElls on chip
| Coordinatore | INTERUNIVERSITAIR MICRO-ELECTRONICA CENTRUM VZW
Organization address
address: Kapeldreef 75 contact info |
| Nazionalità Coordinatore | Belgium [BE] |
| Totale costo | 9˙204˙391 € |
| EC contributo | 6˙999˙999 € |
| Programma | FP7-ICT
Specific Programme "Cooperation": Information and communication technologies |
| Code Call | FP7-ICT-2009-5 |
| Funding Scheme | CP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-09-01 - 2015-02-28 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INTERUNIVERSITAIR MICRO-ELECTRONICA CENTRUM VZW
Organization address
address: Kapeldreef 75 contact info |
BE (LEUVEN) | coordinator | 0.00 |
| 2 |
CONSULTECH UNTERNEHMENSBERATUNG GMBH
Organization address
address: MORGENSTERNSTRASSE 24 contact info |
DE (BERLIN) | participant | 0.00 |
| 3 |
European CanCer Organisation
Organization address
address: Avenue E. Mounier 83 contact info |
BE (Brussels) | participant | 0.00 |
| 4 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: HANSASTRASSE 27C contact info |
DE (MUNCHEN) | participant | 0.00 |
| 5 |
FUJIREBIO DIAGNOSTICS AB
Organization address
address: ELOF LINDALVS GATA 13 contact info |
SE (GOETEBORG) | participant | 0.00 |
| 6 |
ICSENSE
Organization address
address: GASTON GEENSLAAN 9 contact info |
BE (LEUVEN (HEVERLEE)) | participant | 0.00 |
| 7 |
KUNGLIGA TEKNISKA HOEGSKOLAN
Organization address
address: BRINELLVAGEN 8 contact info |
SE (STOCKHOLM) | participant | 0.00 |
| 8 |
Labman Automation Ltd
Organization address
address: ELLERBECK WAY STOKESLEY INDUSTRIAL 2 contact info |
UK (MIDDLESBROUGH) | participant | 0.00 |
| 9 |
MRC HOLLAND B.V.
Organization address
address: Willem Schoutenstraat 6 contact info |
NL (AMSTERDAM) | participant | 0.00 |
| 10 |
MULTID ANALYSES AB
Organization address
address: LOTSGATAN 5 A contact info |
SE (GOTEBORG) | participant | 0.00 |
| 11 |
OSLO UNIVERSITETSSYKEHUS HF
Organization address
address: KIRKEVEIEN 166 TARNBYGGET contact info |
NO (OSLO) | participant | 0.00 |
| 12 |
THINXXS MICROTECHNOLOGY AG
Organization address
address: AMERIKASTRASSE 21 contact info |
DE (ZWEIBRUCKEN) | participant | 0.00 |
| 13 |
UNIVERSITAT ROVIRA I VIRGILI
Organization address
address: CARRER DE ESCORXADOR contact info |
ES (TARRAGONA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
Cancer remains a prominent health concern afflicting modern societies. Continuous innovations and introduction of new technologies are essential to level or even reduce current healthcare spending. As the analysis of occult tumour cells (OTC) in blood or bone marrow is most promising in this respect, MIRACLE aims to develop a low-cost, fully automated, integrated lab-on-a-chip (LOC) system for the isolation, counting and characterization of OTCs starting from clinical samples.A major challenge for OTC detection is their extremely low concentration (below a single cell per mL) in clinical samples. Current detection methods are often based on enrichment techniques followed by cumbersome microscopic analysis of the cell phenotype. Some of these procedure steps have been semi-automated (Cellsearch®, J&J), but the interpretation of the cell morphology requires expertise and remains partially subjective. In contrary to standard phenotyping tests, MIRACLE aims to determine the genotype by integrating all sample processing and detection steps in a miniaturized system. This envisaged, fully-automated MIRACLE test would yield decisive results within half a day for less than 50 EUR, as compared with contemporary diagnostics tests that may take days.With the essential individual modules recently demonstrated on automated chips in a joint project by some of the partners involved (MASCOT FP6 027652), the MIRACLE's consortium is uniquely positioned to lead the project's main objectives to a successful outcome, well ahead of the current state-of-the-art. Combining the team's multidisciplinary and unique expertise avoids unnecessary overlap. Integrating all components into a fully operational LOC platform will represent an immense advance for Europe to cope with interfacing and integration problems generic to microfluidic and smart miniaturized systems. More importantly, the realisation of the MIRACLE vision will revolutionise cancer diagnostics and individualized theranostics.